Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Fluvoxamine for COVID-19: real-time meta analysis of 13 studies
Covid Analysis, December 2022
https://c19early.org/fmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lenze (DB RCT) 93% 0.07 [0.01-0.52] progression 0/80 6/72 Improvement, RR [CI] Treatment Control Lenze (DB RCT) 82% 0.18 [0.05-0.65] hosp. 1/80 5/72 Seftel (QR) 84% 0.16 [0.01-3.29] death/ICU 0/77 2/48 Seftel (QR) 94% 0.06 [0.00-1.04] hosp. 0/77 6/48 Seftel (QR) 99% 0.01 [0.00-0.21] no recov. 0/77 29/48 Lenze (DB RCT) 7% 0.93 [0.42-2.06] hosp. 11/272 12/275 Seo (SB RCT) 0% 1.00 [0.15-6.57] progression 2/26 2/26 Seo (SB RCT) 34% 0.66 [0.06-6.73] progression 1/19 2/25 Seo (SB RCT) 13% 0.87 [0.71-1.06] progression 26 (n) 26 (n) Bramante (DB RCT) -11% 1.11 [0.33-3.61] death/hosp. 6/329 5/324 OT​1 Bramante (DB RCT) -16% 1.16 [0.58-2.25] progression 18/329 15/324 OT​1 Bramante (DB RCT) 2% 0.98 [0.29-3.37] hosp. 5/329 5/324 OT​1 Bramante (DB RCT) 2% 0.98 [0.29-3.37] hosp. 5/329 5/324 OT​1 Bramante (DB RCT) 5% 0.95 [0.72-1.25] progression 79/329 80/321 OT​1 Pineda 96% 0.04 [0.00-0.40] death 1/594 4/63 Pineda 77% 0.23 [0.10-0.51] oxygen 21/594 12/63 Pineda 54% 0.46 [0.21-0.97] hosp. 30/594 10/63 Pineda -36% 1.36 [0.74-2.48] hosp. time 30 (n) 10 (n) Reis (DB RCT) 30% 0.70 [0.37-1.26] death 17/741 25/756 Reis (DB RCT) 91% 0.09 [0.01-0.47] death 1/548 12/618 Reis (DB RCT) 22% 0.78 [0.46-1.28] ventilation 26/741 34/756 Reis (DB RCT) 22% 0.78 [0.61-1.03] hosp. 75/741 97/756 Reis (DB RCT) 32% 0.68 [0.52-0.88] hosp./ER 79/741 119/756 Reis (DB RCT) 31% 0.69 [0.53-0.90] hosp./ER 78/740 115/752 Reis (DB RCT) 66% 0.34 [0.21-0.54] hosp./ER 541 (n) 609 (n) Reis (DB RCT) -49% 1.49 [0.94-2.38] viral+ 167/207 163/221 Calusic (ICU) 42% 0.58 [0.36-0.94] death 30/51 39/51 ICU patients McCarthy (DB RCT) 55% 0.45 [0.04-4.99] hosp. 1/670 2/607 McCarthy (DB RCT) 68% 0.32 [0.01-7.93] progression 0/615 1/565 McCarthy (DB RCT) -10% 1.10 [0.60-1.80] progression 26/670 23/607 McCarthy (DB RCT) -4% 1.04 [0.93-1.15] no recov. 674 (n) 614 (n) McCarthy (DB RCT) -28% 1.28 [0.69-1.88] clin. ord. 670 (n) 607 (n) McCarthy (DB RCT) -17% 1.17 [0.49-2.01] clin. ord. 670 (n) 607 (n) McCarthy (DB RCT) -46% 1.46 [0.79-2.28] clin. ord. 670 (n) 607 (n) Oskotsky (PSM) -58% 1.58 [0.42-5.93] death 2/11 19/165 Oskotsky (PSM) 26% 0.74 [0.55-0.99] death 48/481 956/7,215 Fritz 19% 0.81 [0.26-2.22] hosp./ER 4/17 1,896/20,457 Fritz 12% 0.88 [0.79-0.99] hosp./ER 707/3,414 1,896/20,457 Fritz 12% 0.88 [0.77-0.99] hosp./ER 559/2,744 1,896/20,457 Fritz 10% 0.90 [0.81-0.99] hosp./ER 971/4,577 1,896/20,457 Diaz (PSM) 28% 0.72 [0.63-0.81] cases 4,558 (n) 4,558 (n) Trkulja (PSM) 27% 0.73 [0.35-1.55] death Trkulja (PSM) -37% 1.37 [0.56-3.33] hosp. Fluvoxamine COVID-19 outcomes c19early.org/f Dec 2022 1 OT: comparison with other treatment Favors fluvoxamine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit